Investing in the health care sector isn't easy. Where do you start out? From medical device companies to big pharma to small biotech firms bristling with boom-or-bust prospects, it's tough for investors new to this sector to understand the intricacies unique to health care. Fortunately, there's an easy place to look for blue-chip, tried-and-true stocks: the Dow Jones Industrial Average (DJINDICES:^DJI).
Four big-time health care stocks call the Dow home, but which one is the best pick for your money? In this five-part series, we'll take an in-depth look into why each health care stock on the Dow is worth investing in -- and in the final installment, we'll select a winner. Yesterday we explored the workings of the sector's colossus, Johnson & Johnson; today, let's have a look at one of big pharma's top players: Pfizer (NYSE:PFE).
Opportunities for growth and income investors
While past performance is no indicator of the future, Pfizer's certainly been making investors happy recently. The stock has gained more than 28% over the past 52 weeks and nearly 7% since the start of 2013. Since 2007, Pfizer's stock has outperformed both the S&P 500 index and its peer group of major health care corporations; for long-term investors, this has been a hit.
Recent gains have come despite falling revenue due to patent expirations on top-selling drugs, and with the recent spinoffs of its animal health business and infant nutrition business , Pfizer's been anything but a model of stability. Still, gains are gains.
This isn't just a growth stock, however -- dividend investors should love Pfizer. The company's 3.5% dividend yield ranks among the best yields in the Dow, and Pfizer's 45% payout ratio still leaves the company leeway to maintain its dividend even if hard times come around. Since Pfizer's mainly focused on pharmaceuticals -- as opposed to broad behemoths like Johnson & Johnson -- it's more vulnerable to risks such as patent expirations, generic competition, and failed clinical trials.
Still, dividend investors shouldn't worry: After all, Pfizer is one of the health care sector's biggest players. That's good, because patent expirations have been taking their toll recently.
The here and now of Pfizer's portfolio
Pfizer's revenue fell around 10% last year, and you can thank the loss of patent protection for major blockbuster drug Lipitor, among others, for that. Cholesterol-fighting Lipitor -- once the best-selling drug in history -- saw sales fall around 59% last year; despite that, it still ranked as Pfizer's second-leading seller. However, this company will have to find other routes to future growth with Lipitor over the hill.
Fortunately, Pfizer's best-selling drug in 2012, Lyrica, won't face its own patent expiration until 2018. Lyrica's sales grew by more than 12.5% last year, and with Pfizer testing the drug against new indications, such as for epilepsy patients, it could be primed to grow even more. With more than $4 billion in sales already, Lyrica is one of the key moneymakers for Pfizer's next few years.
But it's hardly the only drug on the market that's making waves -- and isn't staring down the barrel of the patent cliff. Pfizer's pneumococcus vaccine family of Prevnar-13 and Prevenar-13 has grown from receiving FDA approval in 2010 to $3.7 billion in sales in 2012. The vaccine's been a great growth story that's fueling the company's revenues, and with peak sales of $5 billion to $6 billion expected by 2015, it'll team up with Lyrica to power Pfizer past Lipitor's losses and the patent cliff's toll. Investors should keep an eye on Prevnar-13: Earlier this year, the vaccine picked up European approval for expanded use in children and adolescents between the ages of six and 17, a move that should boost its sales abroad.
Boosts to international revenue, such as Prevnar-13's expanded approval, will only help Pfizer overcome falling revenue in the U.S. While American and developed European sales each fell significantly in 2012, revenue in emerging markets climbed by more than 6%. Emerging market sales currently make up 20% of total revenue, but if Pfizer can increase that number and expand its exposure to developing economies – particularly markets such as China and India, where the market for pharmaceuticals is expected to explode as rising middle classes demand better health care -- Pfizer will be looking at a windfall.
There are risks to this, however: Patent protection in emerging economies typically is nowhere near the level of that of advanced economies. The opportunity is massive for Pfizer, but increasing its exposure to emerging markets will bring its own set of new and challenging hurdles. Still, with the U.S. and European markets struggling, investors should expect Pfizer to turn its attention to the brightest developing economies.
Pipelines and beyond
Looking ahead to the future, Pfizer's already laying the groundwork for growth and success.
Pfizer has a robust pipeline of dozens of drugs in development, spread out across a number of different therapies. With so many different medications in the works, the company can afford to strike out on some of them and not risk the business; after all, it only takes a few blockbusters to anchor the revenues of the future.
Pfizer's recently approved blood thinner Eliquis, a drug it made alongside partner Bristol-Myers Squibb (NYSE:BMY), could be that blockbuster. Eliquis impressed in clinical trials, and analysts expect peak sales to climb as high as $5 billion in total for Pfizer and Bristol-Myers by 2017. Another drug further behind in development -- cancer therapy PD-0332991, fresh out of mid-stage clinical trials -- could rise to blockbuster status; Bank of America analysts pegged peak sales at $1 billion if it wins regulatory approval.
On a broader level, Pfizer's smart management decisions recently -- particularly in creating new shareholder value by selling its infant nutrition business for big bucks and spinning off former animal health business Zoetis (NYSE:ZTS) -- inspire optimism in this company's future. Zoetis has surged since its IPO this year, and Pfizer's majority ownership of the company means it'll continue to reap the rewards of Zoetis's climb.
In all, Pfizer's a standout health care stock, and no slouch even among its blue-chip peers on the Dow. Between a powerful pipeline preparing the blockbusters of the future to heady management willing to do what it takes to maximize value, Pfizer's certainly a contender for the best health care stock on the index.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Bank of America and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.